Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

C3250000

Cyclophosphamide

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Cyclophosphamide monohydrate, 2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide, Cytoxan

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C7H15Cl2N2O2P · H2O
Numéro CAS:
6055-19-2
Poids moléculaire :
279.10
Numéro Beilstein :
4678992
Numéro MDL:
MFCD00149395
Code UNSPSC :
41116107
ID de substance PubChem :
329775031
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cyclophosphamide

Fabricant/nom de marque

EDQM

Pf

49-51 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[H]O[H].ClCCN(CCCl)P1(=O)NCCCO1

InChI

1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2

Clé InChI

PWOQRKCAHTVFLB-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cyclophosphamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cyclophosphamide is a cytotoxic nitrogen mustard derivative widely used in cancer chemotherapy. It cross-links DNA, causes strand breakage, and induces mutations. Its clinical activity is associated with a decrease in aldehyde dehydrogenase 1 (ALDH1) activity.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H340,H350,H360FD

Classification des risques

Acute Tox. 3 Oral - Carc. 1B - Muta. 1B - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Ifosfamide European Pharmacopoeia (EP) Reference Standard

I0060000

Ifosfamide

Oxaliplatine United States Pharmacopeia (USP) Reference Standard

USP

1481204

Oxaliplatine

Vincristine sulfate meets USP testing specifications

Sigma-Aldrich

V8388

Vincristine sulfate

Cortisone acetate British Pharmacopoeia (BP) Reference Standard

BP585

Cortisone acetate

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Doxorubicine hydrochloride 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicine hydrochloride

Shivaani Kummar et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(7), 1574-1582 (2015-01-16)
Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of PARP inhibition to the observed clinical activity, we conducted a randomized
Gang Chen et al.
Cancer immunology research, 2(10), 949-961 (2014-08-15)
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide augments vaccine activity in tolerant neu mice and in patients with metastatic breast cancer. HER2-specific monoclonal antibodies (mAb) enhance vaccine activity in neu
Tanja Wenzler et al.
Antimicrobial agents and chemotherapy, 58(8), 4452-4463 (2014-05-29)
African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine
Sebastian Unizony et al.
Arthritis & rheumatology (Hoboken, N.J.), 67(2), 535-544 (2014-10-22)
CD5+ B cells have been conceptualized as a possible surrogate for Breg cells. The aim of the present study was to determine the utility of CD5+ B cells as biomarkers in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). The absolute and relative
Bridget P Keenan et al.
Gastroenterology, 146(7), 1784-1794 (2014-03-13)
Premalignant lesions and early stage tumors contain immunosuppressive microenvironments that create barriers for cancer vaccines. Kras(G12D/+);Trp53(R172H/+);Pdx-1-Cre (KPC) mice, which express an activated form of Kras in pancreatic tissues, develop pancreatic intraepithelial neoplasms (PanIN) that progress to pancreatic ductal adenocarcinoma (PDA).
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique